No Data
No Data
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $5
Editas Medicine Price Target Lowered to $5 From $8 at RBC Capital
TD Cowen Maintains Editas Medicine(EDIT.US) With Buy Rating
Truist Securities Adjusts Editas Medicine's Price Target to $8 From $12, Keeps Buy Rating
Editas Medicine: Strong Cash Position and Strategic Focus on Innovative Gene Editing Programs Drive Buy Rating
Raymond James Downgrades Editas Medicine(EDIT.US) to Hold Rating
No Data
No Data